Pharmacologic Approaches to Prevention and Eradication of Initial Pseudomonas Aeruginosa Infection
Publication Date: October 5, 2014
Last Updated: March 14, 2022
Recommendations
The CF Foundation strongly recommends inhaled antibiotic therapy for the treatment of initial or new growth of P. aeruginosa from an airway culture. (A)
The favored antibiotic regimen is inhaled tobramycin (300 mg twice daily) for 28 days.
322325
The CF Foundation recommends against the use of prophylactic antipseudomonal antibiotics to prevent the acquisition P. aeruginosa. (D)
322325
The CF Foundation recommends routine oropharyngeal cultures rather than bronchoalveolar lavage cultures obtained by bronchoscopy in individuals with CF who cannot expectorate sputum to determine if they are infected with P. aeruginosa. (B)
322325
Recommendation Grading
Overview
Title
Pharmacologic Approaches to Prevention and Eradication of Initial Pseudomonas Aeruginosa Infection
Authoring Organization
Cystic Fibrosis Foundation
Endorsing Organization
American Thoracic Society
Publication Month/Year
October 5, 2014
Last Updated Month/Year
June 27, 2023
Document Type
Guideline
External Publication Status
Published
Country of Publication
US
Target Patient Population
Individuals with CF
Inclusion Criteria
Female, Male, Adolescent, Adult, Child, Infant, Older adult
Health Care Settings
Emergency care, Hospital, Outpatient
Intended Users
Respiratory therapist, nurse, nurse practitioner, physician, physician assistant
Scope
Diagnosis, Prevention, Management, Treatment
Diseases/Conditions (MeSH)
D003550 - Cystic Fibrosis
Keywords
cystic fibrosis, Pseudomonas aeruginosa
Supplemental Methodology Resources
Methodology
Number of Source Documents
46
Literature Search Start Date
May 1, 2012
Literature Search End Date
August 1, 2013